Drug Approval | March 07, 2022
NATCO launches first generic version of Revlimid in the US
NATCO and Teva are launching these strengths of lenalidomide pursuant to a license of patents owned by Celgene
NATCO and Teva are launching these strengths of lenalidomide pursuant to a license of patents owned by Celgene
According to an Injury Surveillance Report by NCA last year, 14.75 % of players sustained shoulder injuries, 13.11% of players sustained knee injuries and almost 74 % players suffer from career-threatening Anterior Cruciate Ligament (ACL) injuries in the 1st two years of return to sport
To mark International HPV Awareness Day on March 4th 2022, the International Papillomavirus Society (IPVS) has warmly welcomed two major advances in the elimination of cervical and anal cancers
Scientists worldwide have started employing wastewater analysis as an efficient and cost-effective approach for assessing the dynamics of the virus in a population. Several scientific methods are being developed to rapidly decode the message carried by sewage
Achieving ML 4 brings Singapore closer to becoming a WHO listed authority, a new scheme that will be operational later this year and will list the world’s regulators of reference
The company, already scaling across Europe, plans to accelerate the deployment of its medication reconciliation platform in the United States
Thermo Fisher and Symphogen extend their collaboration using innovative and efficient workflows to improve data confidence, aiding the creation of new cancer treatments
The method shows the removal of seven types of PFAS – even when all of them are found in the same unit of fluid – at a level of efficiency that approaches 90%, and it does so within a few minutes
Mankind Pharma has agreed to retain Panacea Biotec’s sales and marketing team engaged in this business
Study to evaluate effectiveness of hypoglossal nerve stimulation
Subscribe To Our Newsletter & Stay Updated
